5-Aminomethylbenzimidazoles as potent ITK antagonists

  • Bioorg Med Chem Lett. 2009 Mar 15;19(6):1588-91. doi: 10.1016/j.bmcl.2009.02.012.
Doris Riether  1 ,  Renée Zindell ,  Jennifer A Kowalski ,  Brian N Cook ,  Jörg Bentzien ,  Stéphane De Lombaert ,  David Thomson ,  Stanley Z Kugler Jr ,  Donna Skow ,  Leslie S Martin ,  Ernest L Raymond ,  Hnin Hnin Khine ,  Kathy O'Shea ,  Joseph R Woska Jr ,  Deborah Jeanfavre ,  Rosemarie Sellati ,  Kerry L M Ralph ,  Jennifer Ahlberg ,  Gabriel Labissiere ,  Mohammed A Kashem ,  Steven S Pullen ,  Hidenori Takahashi
Affiliations
  • 1. Medicinal Chemistry Department, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Rd./PO Box 368, Ridgefield, CT 06877, USA.
PMID: 19246196 DOI: 10.1016/j.bmcl.2009.02.012
Abstract

Benzamide 1 demonstrated good potency as a selective Itk inhibitor, however the amide moiety was found to be hydrolytically labile in vivo, resulting in low oral exposure and the generation of mutagenic aromatic amine metabolites. Replacing the benzamide with a benzylamine linker not only addressed the toxicity issue, but also improved the cellular and functional potency as well as the drug-like properties. SAR studies around the benzylamines and the identification of 10n and 10o as excellent tools for proof-of-concept studies are described.

Products